Development and Evaluation of a Vinyl Sulfone-Based Fluorine-18 Labeling Method for Constructing PSMA-targeted Prostate Cancer Imaging Agents
- 26 July 2025
- journal article
- research article
- Published by Springer Nature in Molecular Imaging and Biology
- Vol. 27 (5) , 764-773
Abstract
Purpose Since prostate-specific membrane antigen (PSMA) is widely expressed in nearly all stages of prostate cancer (PCa), PSMA tracers can be considered a viable diagnostic tool for PCa. Compared to 68Ga-labeled PSMA agents, 18F-labeled analogues have various advantages, including the ability to achieve large scale production; easy to commercialize due to its longer half-life; and the ability to image late time points. Because [18F]vinyl sulfone (VS) is a good intermediate for labeling thiol groups in mild conditions with high labeling yield, we explored the use of various VS groups for PSMA modifications in this study. Procedures We developed six 18F-labeled radiotracers targeting PSMA from radioactive intermediates to explore targeting ability and distribution in vivo in LNCaP and 22RV1 tumor-bearing mice. Different labeling methods were compared on their ability to lead to PSMA agents with high contrast and uptake. Results In vitro stability assay showed that the tracer [18F]4a had high stability, with more than 95% of the radiochemical purities remaining as intact forms after 0.5, 1, and 2 h incubation, respectively. In vitro binding assays showed that [18F]4a has a low-micromole binding affinity of 9.45 µM. Cell uptake and internalization assays found that [18F]4a exhibited the highest cell uptake and internalization in 22RV1 cells (1.25 ± 0.06, 1.32 ± 0.11, 1.73 ± 0.08, and 2.03 ± 0.14%ID/106 cells after 10 min, 30 min, 1 h, and 2 h incubation, respectively for cell uptake assay; 0.52 ± 0.02, 0.70 ± 0.11, 0.78 ± 0.04, and 0.98 ± 0.15%ID/106 cells after 10 min, 30 min, 1 h, and 2 h incubation, respectively for cell internalization assay.) Analysis of the PET images showed that the tracer [18F]4a had the highest tumor uptake (3.38 ± 0.35%ID/g at 2 h p. i. in 22RV1 tumor-bearing mice; 30.16 ± 13.00%ID/g at 2 h p. i. in LNCaP tumor-bearing mice.) Of note, the tracer [18F]4a showed an approximately threefold increase in tumor uptake compared to [68Ga]PSMA-11 in LNCaP tumor-bearing mice at 2 h p. i. The biodistribution experiment verified the accuracy of the in vivo distribution of [18F]4a in LNCaP and 22RV1 tumor-bearing mice by PET/CT imaging. Conclusions PSMA-targeted radiotracer [18F]4a is a promising PET agent for prostate cancer diagnosis.Keywords
Funding Information
- Luzhou Science and Technology Bureau (2021LZXNYD-J23)
- Science and Technology Department of Sichuan Province (2022YFS0608)
- National Natural Science Foundation of China (U20A20384)
This publication has 26 references indexed in Scilit:
- Evaluation of sulfone-labeled amino acid derivatives as potential PET agents for cancer imagingNuclear Medicine and Biology, 2022
- New PET Radiotracers for the Imaging of Neuroendocrine NeoplasmsCurrent Treatment Options in Oncology, 2022
- Development of high-affinity fluorinated ligands for cannabinoid subtype 2 receptor, and in vitro evaluation of a radioactive tracer for imagingEuropean Journal of Medicinal Chemistry, 2022
- Development of 18F-Labeled Vinyl Sulfone–PSMAi Conjugates as New PET Agents for Prostate Cancer ImagingMolecular Pharmaceutics, 2021
- FDA Approves Ga 68 PSMA-11 for Prostate Cancer ImagingInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2021
- Comparing the diagnostic performance of radiotracers in recurrent prostate cancer: a systematic review and network meta-analysisEuropean Journal of Nuclear Medicine and Molecular Imaging, 2021
- RXH-Reactive 18F-Vinyl Sulfones as Versatile Agents for PET Probe ConstructionBioconjugate Chemistry, 2020
- F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patientsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2016
- Diagnostic Efficacy of 68 Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate CancerJournal of Urology, 2016
- Initial Evaluation of [18F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate CancerMolecular Imaging and Biology, 2015